source
- Genmab's bispecific combo with Keytruda halves death risk in phase 3 head‑neck cancer trialGenmab announced interim results from its phase 3 LiGeR-HN1 study, showing that adding the bispecific antibody petosemtamab to Merck's Keytruda significantly improved outcomes for patients with PD-…
- Lilly's retatrutide outperforms Ozempic in weight loss and blood sugar reduction in head-to-head diabetes trialEli Lilly reported that its experimental drug retatrutide showed greater efficacy than Novo Nordisk’s Ozempic in a large diabetes trial. After 80 weeks, participants receiving the highest dose of…